Plain-English translation of NCT06807619 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a medication called to see how well it works against brain tumors that have a specific genetic mutation called KRAS G12C. Researchers want to understand whether the medication can actually reach the tumor in the brain, how safe it is, and whether it helps people whose tumors are being surgically removed. The study will also track how your body absorbs and processes this treatment.
Many brain tumors are hard to treat because medications struggle to cross the blood-brain barrier—a protective layer around the brain. This trial exists to learn whether this medication can penetrate brain tumors effectively and potentially offer hope to patients with this particular genetic type of brain cancer.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will receive , either at the standard dose (if you haven't taken it before) or at a dose your doctor previously prescribed (if your tumor has progressed on earlier treatment). You will also undergo your planned brain surgery to remove or biopsy the tumor. Researchers will conduct blood tests and imaging scans to measure how well the medication reaches your tumor, how your body handles it, and whether it is safe and effective for you.
AI-generated summary from trial data · Jun 13, 2026 · Not medical advice
United States